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Abstract
Medicinal plants have long been an excellent source of pharmaceutical agents. Accordingly, the long
term objectives of the author's research program are to discover and design new chemotherapeutic
agents based on plant-derived compound leads by using a medicinal chemistry approach, which is a
combination of chemistry and biology. Different examples of promising bioactive natural products
and their synthetic analogs, including sesquiterpene lactones, quassinoids, naphthoquinones,
phenylquinolones, dithiophenediones, neo-tanshinlactone, tylophorine, suksdorfin, DCK, and DCP,
will be presented with respect to their discovery and preclinical development as potential clinical
trial candidates. Research approaches include bioactivity- or mechanism of action-directed isolation
and characterization of active compounds, rational drug design-based modification and analog
synthesis, as well as structure-activity relationship and mechanism of action studies. Current clinical
trials agents discovered by the Natural Products Research Laboratories, University of North Carolina,
include bevirimat (dimethyl succinyl betulinic acid), which is now in Phase IIb trials for treating
AIDS. Bevirimat is also the first in a new class of HIV drug candidates called “maturation inhibitors”.
In addition, an etoposide analog, GL-331, progressed to anticancer Phase II clinical trials, and the
curcumin analog JC-9 is in Phase II clinical trials for treating acne and in development for trials
against prostate cancer. The discovery and development of these clinical trials candidates will also
be discussed.
Introduction
In the Natural Products Research Laboratories (NRPL), our objectives are to discover and
develop bioactive natural products and their analogs as clinical trials candidates. The three
approaches used to achieve these objectives are (1) bioactivity- or mechanism of action-
directed isolation and characterization of active compounds, (2) rational drug design-based
modification and analog synthesis, and (3) mechanism of action (MOA) studies. The scientific
disciplines covered include natural products chemistry, molecular biology and biochemistry,
and pharmacology, to discover promising new leads based on bioactivity- or mechanism of
action-directed approaches; medicinal chemistry and synthetic organic chemistry to achieve
new leads optimization based on modern medicinal chemistry approaches; and analytical
chemistry to apply state-of-the-art analytical instrumental chromatography technologies to
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support the above two tasks. MOA and in vivo evaluation studies are supported by
collaborations with more than 60 active established researchers worldwide to enhance the
programs of the NPRL. Current research programs in the NPRL include the investigation of
(1) novel plant cytotoxic antitumor and anti-HIV principles and synthetic analogs as antitumor
and anti-AIDS agents and (2) other chemotherapeutic agents, such as antimalarial, antifungal,
antiviral and anti-inflammatory agents, as well as (3) traditional Chinese medicines (TCM),
targeting to their active principles, fractions and prescriptions.
General Concepts on Drug Discovery and Development
Drug discovery can build on several sources; however, my laboratories focus on bioactivity-
directed isolation and characterization of lead natural product principles from single medicinal
herbs and formulations. As shown in Figure 1, the subsequent preclinical optimization of a
lead compound is an cyclical process of obtaining bioassay screening results, analyzing activity
data, designing new target compounds, and synthesizing new analogs.1 In this iterative process,
I feel that chemistry and biology are complementary and co-dependent areas of science, similar
to the Chinese concepts of Yin and Yang – one is not present or sufficient without the other
(Figure 2). The discovery of new bioactive compounds depends on valid biological assays,
while new chemistry can make the discovery of new biological targets possible. I feel that
medicinal chemistry combines techniques from chemistry and from biology to facilitate new
drug discovery. By using these concepts and techniques, my NPRL has been able to discover
more than 3,000 bioactive natural products and their synthetic derivatives/analogs since 1971,
as briefly summarized below.
Antitumor Agents
Sesquiterpene Lactones
Helanalin and Its Analogs. In the mid-1970s, three sesquiterpene lactones, molephantin (1),2
molephantinin (2),3 and phantomolin (3) (Figure 3)4 were discovered as new cytotoxic
principles from Elephantopus mollis. The latter two compounds showed similar T/C values
(397% and 378%, respectively) against Walker 256 carcinoma (W-256) in rats (dose = 2.5 mg/
kg). Microlenin (4), a structurally related dimeric sesquiterpene lactone from Helenium
microcephalum, had a T/C value of 173% against W-256 (dose = 2.5 mg/kg),5 while its
monomer, helenalin (5), had a T/C value of 316% under the same conditions (Figure 4).
Helenalin contains both an α-methylene-γ-lactone moiety, and an α,β-unsaturated ketone;
therefore, studies were performed to determine the relative contributions of the two O=C-
C=CH2 systems. The rank order of potency against Hep-2 human epidermoid laryngeal
carcinoma was 5 (ED50 0.08 μg/mL) > 11,13-dihydrohelenalin (6) (ED50 0.80 μg/mL) > 2,3-
dihydrohelenalin (7) (ED50 3.84 μg/mL) > 2,3,11,13-tetrahydrohelenalin (8) (inactive) (Figure
5).6 Thus, reduction of the double bond of the α,β-unsaturated ketone had a greater effect on
potency than reduction of the α-methylene-γ-lactone. In mechanistic studies, the cytotoxicity
of helenalin and structurally related sequiterpene lactones was linked to a Michael-type
addition reaction of the O=C-C=CH2 systems in the molecule with sulfhydryl groups of
reduced glutathione and L-cysteine.7,8 Finally, bis(helenalinyl) esters (two helenalin molecules
connected through their hydroxy group by a diester linkage) were generally more potent and
less toxic than the parent alcohol.9 At 8 mg/kg, 5 had a T/C of 162% against P388 leukemia
in mice, while bis(helenalinyl)glutarate (9, Figure 6) had a T/C of 195%.9
Quassinoids: Brusatol and Its Analogs
The fruits of Brucea javanica (Chinese medicine “Ya-Tan-Tzu”) yielded many new
quassinoids, including several compounds with significant cytotoxicity against various
cancers, such as bruceosides A-F (10–15) and brusatol (16) (Figure 7).10-12 Bruceantin (17),
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which has a terminal isopropyl rather than methyl group in the C-15 ester side chain compared
with 16 (Figure 7), was previously isolated from B. antidysenterica by Kupchan et al. by
bioactivity-guided fractionation.13 Our laboratories first reported two synthetic methods for
the conversion of 10 into 17, which was in anticancer clinical trials.14 Connecting two
molecules of 16 or 17 at the C-3 hydroxy group through malonate, glutarate, adipate, and
sebacate esters gave bis-esters (18–23, Figure 8) that were as active or more active than the
parent alcohols against P-388 leukemia.15 In addition to C-3 esterification, other structural
features essential for enhanced cytotoxic activity include free hydroxy groups at C-11 and -12,
an enone double bond in ring A, and an unsaturated ester at C-15.16,17 The identity of the C-15
ester side chain can significantly affect cytotoxicity, and oxidation of the C-15 side chain has
been postulated to cause deactivation of 16- or 17-related quassinoids. Therefore,
trifluoromethyl groups were incorporated into the side chain at this position, as well as in the
C-3 ester side chain. The most potent analog was 15-[3'-trifluoromethyl)-butanoyl]-bruceolide
(24, Figure 8), which had similar potency and log GI50 values (-7.0 – -8.7) compared with
17 against a human cancer cell line panel.18
Phenylquinolones and Naphthyridinones: NSC-656158 and Its Analogs
The natural flavonoids, tricin (25) and kaempferol-3-O-β-D-glucopyranoside (26), and the
lignan (+)-nortrachelogenin (27) were isolated by bioactivity-guided fractionation as
antileukemic principles from Wikstroemia indica (Figure 9).19 2-Phenyl-4-quinolones are
structurally related compounds with nitrogen rather than oxygen in the heterocyclic ring.
Synthetic modification led to several fluorinated 2-phenyl-4-quionolones as potent antimitotic
antitumor agents. NSC-656158 (28, Figure 10) showed potent cytotoxicity against a human
tumor cell line (HTCL) panel (average log GI50 -6.47), inhibited tubulin polymerization
(IC50 0.85 μM), and exhibited good in vivo antitumor activity (130% prolonged life span of
mice bearing OVCAR-3 xenografts).20 An analog (29, Figure 10) substituted with a pyrollidine
ring rather than methylenedioxy group was even more potent with an average in vitro log
GI50 of -7.65 and tubulin inhibitory IC50 of 0.46 μM.20 Mechanistically, 28 inhibits hepatocyte
growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by
suppressing matrix metalloproteinase-9 expression at the micromolar range. Therefore, 28 is
a potential therapeutic agent against tumor invasion.21 2-Aryl-1,8-naphthyridin-4(1H)-ones
were also synthesized as antimitotic antitumor agents. 3'-Methoxy and halogenated-2-phenyl
compounds (29–32), as well as 2-(α-naphthyl) (33) but not 2-(β-naphthyl) compounds, were
highly active in both antitumor and antitubulin assays, with average log GI50 values comparable
to those of positive controls colchicine and podophyllotoxin (Table 1).22 The identities of the
halogens on the 2-phenyl ring and of substituents on the pyridine ring of the naphythyridinone
system also influenced the tumor cell line selectivity at the total growth inhibition level.22
Naphthoquinones and Dithiophenedione Analogs
Psychorubrin (34, Figure 11) from Psychotria rubra is a cytotoxic natural product with a
naphthoquinone skeleton. Related compounds with furanonaphthoquinone (35) and
naphthothiophenedione (36–38) skeletons (Figure 11) also show potent cytotoxicity.23
Continued work led to a series of potent 2- and 3-methyl-4,8-dihydrobenzo[1,2-b:5.4-b']
dithiophene-4,8-diones (39–46, Figure 12). Several compounds showed high cytotoxic activity
against melanoma, non-small cell lung cancer, and breast cancer cell lines. 2-
Hydroxymethyl-4,8-dihydrobenzo[1,2-b:5.4-b']dithiophene-4,8-dione (42) showed the
highest activity against melanoma (mean log GI50 = -7.74) and the highest overall potency
(mean log GI50 = -6.99) against the NCI HTCL panel.24 Dithiophene compounds were also
found to significantly enhance retinoic acid-induced differentiation in leukemia cell lines. N-
(2-Dimethylaminoethyl)-4,8-dihydrobenzo[1,2-b:5.4-b']dithiophene-4,8-dione-2-
carboxamide (47, Figure 12) showed the greatest effect, inducing nearly complete
differentiation at 0.02 μM.25
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Both colchicine (48) and thiocolchicine (49) are potent antimitotic agents, inhibiting tubulin
polymerization with IC50 values of 1.5 and 0.65 μM, respectively.26 Thiocolchicone (50–54)
derivatives, which have an oxygen moiety rather than a acetamido group at C-7, showed
comparable or greater activity in tubulin polymerization, colchicine-binding, and cytotoxicity
assays (Figure 13).27 Allocolchinoids (55–57), with a six-membered rather than seven-
membered C-ring, also showed significant antitubulin effects and cytotoxicity, even against
three drug-resistant KB cell lines compared with the parental KB cell line (Table 2).28
Epipodophyllotoxins: GL331 and Its Analogs
Podophyllotoxin (58) is a natural lignan found in Podophyllum peltatum (or Mayapple) and
related species. It inhibits mitosis by preventing polymerization of microtubules into tubulin.
In contrast, etoposide (59) and teniposide (60), two semi-synthetic glycosidic 4'-
demethylepipodophyllotoxin derivatives (Figure 14),29 do not affect tubulin, but instead act
by inhibiting DNA topoisomerase II (topo II).30 Although they are used clinically against
various cancers, both compounds are poorly bioavailable, can cause myelosuppression, and
suffer from drug resistance.30 As a possible solution, 4-alkyl-,31 benzyl-,32 and aryl-32 amino
analogs of 4'-demethyl-epipodophyllotoxin were synthesized. Many compounds exhibited
more potent DNA topo II inhibition and a greater percentage of protein-linked DNA breakage
compared with etoposide.32 When compared with etoposide, several arylamino compounds
(61–66) were as cytotoxic against KB cells and more active against three KB cell lines (KB1C,
KB7D, KB50) showing resistance to etoposide (Table 3).32,33 GL331 [4'-O-demethyl-4β-(4”-
nitroanilino)-4-deoxypodophyllotoxin] (63) emerged as the lead compound from these studies.
Compound 63 (NSC-628679) was tested in Phase I anticancer clinical trials at M.D. Anderson
Cancer Center, after favorable toxicological evaluation by Genelabs Technologies, Inc.
(Redwood City, CA). It showed markedly favorable results in these trials, with primary
indications against colon and small cell lung cancers, and progressed to Phase II clinical trials.
Advantages of 63 over etoposide are easier manufacture, greater activity, particularly against
drug-resistant cancer cell lines, and possibly a superior safety profile.34 A Comparative Field
Analysis (CoMFA) computer model was generated using 102 epipodophyllotoxin, which
showed that active compounds should have a positively charged functional group near the DNA
minor groove.35 Subsequent new analogs are shown in Figure 15. Adding bulky tails at the
para position of the 4'-aniline resulted in improved activity profiles. Analog 67 with a
pyrollecarboxamidine moiety displayed increased cytotoxicity (ED50 = 0.04 and 0.2 μM)
compared with etoposide (ED50 = 0.2 and 25 μM) against both KB and KB-7d cells.36
Similarly, compound 68 with an amino acid (benzyl L-alanyl-N-carbonyl) incorporated at this
same position showed even better activity (ED50 KB = 0.5 μg/mL, KB-7d = 0.25 μg/mL) than
63 (ED50 = 0.2 μg/ml, 2 μg/mL) against drug resistant cell lines.37 Finally, the 4'-hydroxy
group of 4β-para-substituted arylamino-epipodophyllotoxin analogs was esterified with N,N-
dimethylglycine (69) to enhance drug resistance and water solubility simultaneously.
Cytotoxicity and drug resistance profiles of most analogs were similar to those of 63, while
esterification caused some decrease in protein-linked DNA breaks and, thus, perhaps
interaction with DNA.38
Curcumins: JC-9 (ASC-J9) and Its Analogs
The diarylheptanoid curcumin (70, Figure 16) is found in Curcuma longa and other related
species. The rhizomes of these plants are used as both spices (turmeric) and medicines,
particularly for hepatic disorders. Curcumin and other polyphenolic curcuminoids give
turmeric its yellow color and stimulate bile secretion in the treatment of hepatitis. Curcumin
itself shows moderate inhibitory activity against prostate cancer cell lines, and synthetic
modifications yielded two lead compounds, JC-9 (71) and LL-80 (72), with increased activity
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against PC-3 (IC50 = 1.1 and 1.0 μM, respectively) and LNCaP (IC50 = 1.3 and 0.2 μM,
respectively) cell lines.39,40 Compound 71 (also known as ASC-J9) was licensed by
Androscience Corp. (San Diego, CA), and has succeeded in Phase II clinical trials against acne.
Anti-prostate clinical trials with 71 are being planned. Mechanistically, 71 enhances androgen
receptor degradation.41-43
Neo-tanshinlactone Analogs
The rhizomes of Salvia miltiorrhiza are well known in TCM as “Tanshen” and used mainly to
treat coronary disorders, such an angina pectoris. Among its lipophilic bioactive constituents
are the tanshinones, including tanshinone I (73) and IIA (74) (Figure 17). The water-soluble
sulfonate (75) of the latter compound may act as a calcium antagonist and anti-calmodulin drug
similar to the clinically used verapamil. Another related constituent of “Tanshen” is neo-
tanshinlactone (76), which has a lactone rather than o-quinone ring-C (Figure 17).44 This
compound showed selective cytotoxicity against two estrogen receptor-positive (ER+) breast
cancer cell lines, MCF-7 and ZR-75-1, and was ten-fold more potent than tamoxifen.45 In initial
SAR studies, 4-ethyl-neo-tanshinlactone (77) was even more potent (ED50 = 0.45 and 0.18
μg/mL) than neo-tanshinlactone against these two cell lines, and, in addition, potently inhibited
(ED50 = 0.1 μg/mL) the SK-BR-3 breast cancer cell, which is estrogen receptor negative (ER-),
but over-expresses HER2 (HER2+).46 In SAR analog studies, the aromatic rings A and D were
found to be important for anti-breast cancer activity. In addition, certain ring C-opened analogs
(80, 82) retained activity and had increased selectivity towards specific breast cancer subtypes
(Table 4).47,48 The lead compound 76 was also tested in vivo against cancer cell xenografts in
mice. At 10 mg/kg, it remarkably delayed tumor growth compared to control, and thus, showed
significant and selective antitumor activity against the human ZR-75-1 breast ductal carcinoma
xenograft.49
Phenanthrene-Based Tylophorines: PBT-1 and Its Analogs
Tylophorine (83), antofine (84) and other phenanthroindolizidine alkaloids found in the genus
Tylophora are collectively known as Tylophora alkaloids (Figure 18). Several such compounds
have shown activity against various cancer cell lines, including refractory cancers. One of these
compounds, tylocrebine (85), reached anticancer clinical trials, but failed due to central nervous
system (CNS) toxicity.50 Structurally simplified phenanthrene-based tylophorine (PBT)
analogs (86–89, Figure 18), which lack the indolizidine ring system found in the natural product
leads, were synthesized through an efficient five-step route.51 The new compounds have a core
phenanthrene substituted with an aminosubstituted methylene at the 9-position. The amine
group could be an alkylamino, pyrrole, piperidine, or piperazine with a terminal carboxy or
preferably a hydroxy group.52,53 N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-yl-methyl)-
L-piperidinemethanol (86, PBT-1) emerged as the lead compound from SAR studies. It showed
good cytotoxic activity against various cancer cell types with IC50 ranging from 0.04–0.07
μM. Its hydrochloride salt (87) also showed moderate in vivo activity against A549 lung cancer
xenografts in mice, without CNS toxicity.52 Interestingly, mechanistic studies showed that
natural Tylophora alkaloids and the structurally related synthetic PBT analogs do not share the
same mechanism of action (Figure 19).53 Additional studies showed that 86 induced cell cycle
arrest at the G2/M phase, accompanied by accumulation of cyclin B1 and activation of the
MAPK signaling pathway, similar to paclitaxel.54 In addition, 86 induced apoptosis by
inactivating Akt and inhibiting the NF-κB pathway.54 Lead PBT compound 86 or a new analog
will likely be a good candidate for anticancer clinical trials.
Conjugated Paclitaxel Analogs
Figure 20 shows examples of various conjugated paclitaxel analogs. First, a taxoid (either
paclitaxel or cephalomannine) was conjugated at its 2'- and/or 7-position through an imine
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linkage to a 4β-amino-4'-O-demethylepipodophyllotoxin derivative.55 Several compounds
(e.g., 90) showed comparable or better cytotoxic activity than the unconjugated
epipodophyllotoxin, and showed enhanced activity against paclitaxel-resistant cancer cell
lines.55
Similarly, paclitaxel was also conjugated with a camptothecin derivative.56 Compared with
camptothecin, all of the new conjugates (e.g., 91–93) showed higher cytotoxicity, but lower
inhibition of topo I. Against HCT-8 cancer cells, the conjugates were also more active than
paclitaxel, suggesting a different spectrum of activity, and thus, possibly a novel mechanism
of action.56
Several different dietary antioxidants (including vitamin E, curcumin, dehydrozingerone, 4-
methylumbelliferone, and others) were conjugated to the 2'-hydroxy group in the paclitaxel
side chain through an ester linkage.57 Many of the compounds showed selective cytotoxicity
against certain cancer cell lines, particularly the 1A9 and KB cell lines. The paclitaxel-vitamin
E conjugate (94) with a glycine ester salt at the C-7 OH of paclitaxel exhibited notable inhibition
against pancreatic cancer (Panc-1) cells with a lesser effect on the normal (E6E7) cell line, and
is a good candidate for further studies.57
Chromenones: Desmosdumotin and Protoapigenone Analogs
Desmosdumotins B (95) and C (96) are bioactive flavanoids from in Desmos dumosus. A short
efficient route to both compound types was established (Scheme 1). Among 96-type chalcones,
a 4-bromo-3',3',5'-tripropyl analog (97) was the most potent with EC50 values of 0.9–2.3 μg/
mL against seven different cancer cell lines, compared with 3.0–11.1 μg/mL for
desmosdumotin C.58 Among 95-type flavones, the naphthyl substituted 98 showed potent
cytotoxicity against all six cancer cell lines tested, with EC50 values of 0.2–0.6 μg/mL. 6,8,8-
Triethyl substituted compounds (e.g., 99), particularly when coupled with 4'-methyl or -ethyl
substituents on the pendant phenyl ring, showed notable cytotoxicity (EC50 0.03 and 0.025
μg/mL, respectively) and selectivity against vincristine-resistant KB cell lines (KB/KB-vin
>460 and 320, respectively).59 Protoapigenone (100) is structurally related to 95, but has an
unusual non-aromatic B-ring with a hydroxy group on the C-1' position. The first total synthesis
of this compound also allowed for preparation of modified analogs (Scheme 2). Initial SAR
study showed that changing the C-5 and C-7 A-ring hydroxy groups to methoxy groups (e.g.,
101) or changing the phenyl A-ring to a naphthyl ring system (102) increased the cytotoxicity
when compared to 100. Analogs 101 and 102 had comparable potency to that of doxorubicin
against liver and breast cancer cell lines, respectively.60
Kalanchosides
Three new bufadienolides (kalanchosides A–C, 103–105) were isolated from the medicinal
herb Kalachoe gracilis. These compounds showed remarkably potent cytotoxicity against a
HTCL panel, particularly against the A549 lung cancer cell line, where the EC50 value of
103 was 0.5 ng/mL (Table 5).61
Summary of the Highlights of Antitumor Agents Discovered by NPRL in Clinical Trials and
in Preclinical Studies
Numerous compounds with potent cytotoxicity have been discovered as new drug candidates
through studies in the author's NPRL, and have been reviewed before in this journal.62 A
summary and highlights in regard to the above compounds are given in Figure 21.
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Artemisia annua was long used as a medicinal plant for malaria fever, and artemisinin (106)
(“Qing Hao Su”), isolated from this plant, was used as a safe and effective cure for malaria in
mainland China.63 Artemether (107) and arteether (108) are semi-synthetic derivatives that are
used clinically to treat drug-resistant malaria and as a second-line therapy for severe malaria
cases, respectively.64 A simpler endoperoxide (C-O-O-C-C=C) analog (109) synthesized from
α-santonin was not active, which showed that the unique 1',2',4'-trioxane ring (C-O-O-C-O-C)
could be quite specific for activity, because a simpler cyclic epoxide ring was not adequate.
65 Subequent synthetic studies to explore this issue resulted in several desethanoqinghaosu
analogs, both cyclic peroxide lactone (110) (C-O-O-C-O-C-O-C=O),66 as well as non-lactone
(111, 112) (C-O-O-C-O-C-O) compounds,66 and 12-deoxo (113, 114) (C-O-O-C-O-C-O-C)
67 analogs. All of these compounds were less potent than 106. However, tricyclic 1',2',4'-
trioxane acid hydrolysis products (115, 116) of 106, in which the lactone ring was opened,
were equipotent to the tricyclic parent compound. Thus, the ethane bridge forming the fourth
ring is essential for potent activity, and likely imposes a strict steric stricture on the 1',2',4'-
trioxane ring.68 More recent studies by Posner et al. with a structurally related compound
(117) have supported these earlier findings.69 Compounds of interest are shown in Figure 22.
Antifungal Agents
Anthracenediones substituted with 2',3'-epoxypropylamino groups were found to be potent
antibacterial and antifungal agents. The compounds combined structural features of
mitoxantrone (118), an anthracenedione antineoplastic agent, and teroxirone (119), an
experimental triepoxide antitumor agent (Figure 23). 1,4-Di-(2,3-epoxy-propylamino)
anthracenedione (120) had a minimum inhibitory concentration (MIC) of less than 0.13 ppm
against Pseudomonas fluorescens, Staphylococcus aureus, Aspergillus niger, and
Aureobasidum pullulans, but was less active against Ps. aerugenosa (MIC = 63 ppm) and
Escherichia coli (MIC = 250 ppm).70 Compound 120 was licensed by Rohm and Haas
Company (Philadephia, PA) for use as an antifungal agent.
Anti-AIDS Agents
The life cycle of human immunodeficiency virus (HIV), the causative agents of AIDS, offers
various points for chemotherapeutic attack. Many anti-HIV agents inhibit the actions of the
viral enzymes, including reverse transcriptase (nucleoside and non-nucleoside reverse
transcriptase inhibitors, NRTIs and NNRTIs), protease (protease inhibitors, PIs), and integrase
(integrase inhibitors, IN). Drug/drug candidates that inhibit other viral processes include
maturation inhibitors (MIs), which inhibit virus budding/maturation, and entry inhibitors,
which inhibit viral adsorption, chemokine co-receptor binding, or virus-cell fusion. The
NPRL's anti-AIDS research program focuses on discovering lead natural products with
promising anti-HIV activity, which can offer new structural and mechanistic classes of drug/
drug candidates, particularly as viral resistance to currently used agents is a growing problem
and limits therapeutic options. The earliest work led to the discovery of four new
tetragalloylquinic acids, which at least in part inhibited HIV RT transcriptase activity.71
Continued studies have led to numerous natural products from various chemical classes with
promising anti-HIV activity, based primarily on initial results from a screening to determine
the level of HIV infection in treated cells. Examples (121–131) are given in Table 6.72-92 More
detailed discussion will be given on two compound classes: betulinic acid derivatives and
suksdorfin derivatives.
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3-O-(3',3'-Dimethylsuccinyl)betulinic Acid (DSB, Bevirimat): Maturation Inhibitors
A prior review93 described the identification of the triterpene betulinic acid (130) as an anti-
HIV lead compound, followed by the identification of its ester analog, 3-O-(3',3'-
dimethylsuccinyl)-betulinic acid (DSB, 133) (Figure 24), as the first HIV maturation inhibitor,
through SAR modification, mechanism of action, and preclinical studies. A brief description
of these studies will be given here.
In 1994, 130 was isolated as anti-HIV principle from leaves of Syzigium claviflorum (“Pang
Hua Chih Nan”).91 It is also found in the bark of the London plane tree (Platanus acerifolia),
and its precursor betulin (134) in the bark of white birch (Betula alba) (Figure 24). Among a
series of 3-acyl derivatives of 130, 133 was found to be the most potent compound (Table 7,
135–140).94 It was licensed to Panacos Inc. (Watertown, MA), renamed PA-457 and then
Bevirimat, and subjected to intensive preclinical studies. It was a potent inhibitor of primary
HIV-1 isolates in vitro, retained activity against virus isolates resistant to NRTIs, NNRTIs,
and PIs, and also showed synergistic effects with other AIDS drugs. In mechanistic studies,
133-treated HIV virions showed immature, spherical cores.95 Studies suggested that 133
interferes with normal gag processing, which is necessary to form mature infectious virus
particles. Indeed, further research proved that 132 disrupts cleavage at the CA-SP1 junction of
the gag precursor protein, and disrupts normal capsid condensation. The resulting virus
particles are defective and noninfectious. In summary, 132 was found to be the first-in-class
HIV maturation inhibitor, targeting the CA-SP1 region of gag.88,95 Compound 133 was easily
formulated as in a salt form with good oral availability, was eliminated via glucuronidation,
and was active in a SCID mouse model.96 In Phase I clinical trials, it was safe and well tolerated
with a good half-life and plasma levels.97 In Phase II clinical trials, 133 reduced viral load
significantly (mean of -1.18 log10 copies/mL after 14 days of treatment) with good plasma
levels found with a tablet formulation.97 It has now been licensed to Myriad Pharmaceuticals
(Salt Lake City, UT), which has renamed the compound “MPC-4326” and is planning Phase
III clinical trials for 2009/2010. The US FDA granted “Fast-Track” new drug development
status for 133, for treatment of HIV in combination with already approved drugs or possibly
as a first-line therapy. Figure 25 summarizes the status of the clinical development of 133.
(3'-Monomethylsuccinyl)betulinic Acid (MSB) Analogs
More recently, the 3' S-methyl group was found to be the main contributor to the extremely
high anti-HIV potency, because 3'S-MSB (S-141) was much more active than 3'R-MSB
(R-141) (Table 8).98
C-28 Amide Substituted Analogs: Entry Inhibitors
For anti-HIV maturation activity, the C-3 position of betulinic acid analogs was found to be
the pharmacophore for anti-HIV maturation activity (Figure 26). For optimal potency, the
analog should have a C-3 acyl side with the proper length, terminal carboxylic acid moiety,
and dimethyl substitution at the C-3' position for optimal potency.93,97 However, prior studies
by Soler et al. showed that betulinic acid derivatives substituted with ω-aminoalkanoic acid at
the C-28 position, e.g., RPR103611 (142, Figure 27), showed anti-HIV activity in the
nanomolar range, by interfering with the virus-cell fusion process.99 Thus, the C-28 position
of betulinic acid is the pharmacophore for anti-HIV entry activity (Figure 26).99,100 Addition
of two ω-aminoalkanoic acids (m=7-10, n=3 or 4) resulted in optimal activity. Both statine and
L-leucine, as the terminal amino acid, gave potent analogs, as evaluated in the MAGI assay for
HIV-1 entry inhibitors.101 The exact target of these triterpene entry inhibitors has not been
determined, although viral mutations that confer resistance were found in gp41 for RPR103611
and gp120 for its stereoisomer IC9564 (143, Figure 27).100
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C-3, C-28 Disubstituted Inhibitors: Bifunctional Inhibitors
Addition of an appropriate acyl side chain at C-3 and amide side chain at C-28 to betulinic acid
results in derivatives that inhibit both HIV entry and maturation.100 In SAR studies, the lead
compound A12-2 (144; dimethylsuccinyl at C-3, 7-aminoheptanoic acid at C-28) was at least
20 times more potent at inhibiting HIV replication than either 130 (C-3, but not C-28
substituted; maturation inhibitor only) or 143 (C-28, but not C-3 substituted; entry inhibitor
only), as well as demonstrating both anti-maturation and anti-entry activities (Figure 28).102
In SAR studies, smaller and bulkier C-3 acyl side chains were detrimental to activity.103 At
the C-28 position, forming the amide bond by using a cyclic secondary amine, such as
piperidine, increased metabolic stability.104 Regarding the triterpene molecular scaffold,
moronic, ursolic, and oleanolic acid analogs were active, while glycyrrhetinic and lithocholic
acid analogs were not.103,105 In fact, moronic analog 145, which is substituted with a 3',3'-
dimethylsuccinyl ester at C-3 and L-leucine amide at C-28, showed better potency than
bevirimat against several HIV strains (EC50 values against NL4-3 were 0.0085 μM/0.096 μM
and against PI-R were 0.021 μM/0.43 μM). Thus, 145 could be another promising clinical trial
candidate in the triterpene class.
Suksdorfin Derivatives
Dicamphanoylkhellactone (DCK) Analogs
Bioactivity-directed fractionation using a p24 antigen ELISA assay for HIVIIIB replication in
H9 lymphocytes led to the isolation of the natural coumarin suksdorfin (132) as an anti-HIV
principle (EC50 = 1.3 μM, TI >40) from Lomatium suksdorfii.106 Replacing the two natural
acyl groups with various esters led to the synthesis of the new anti-HIV lead 3',4'-di-O-(-)-
camphanoyl-(+)-cis-khellactone (146, DCK) (Figure 29), which had greatly increased potency
(EC50 = 0.049 μM, TI >328).77,106 Compound 146 and its derivatives could be prepared
efficiently through a synthetic route developed using a Sharpless asymmetric dihydroxylation
(Scheme 3).107,108 In initial SAR studies, methylation at the 4- or 5-position of the coumarin
ring greatly increased potency, resulting in EC50 and TI values of 0.006 μM/6,600 (4-MeDCK,
148) and 0.0086 μM/>2,000 (5-MeDCK, 149) (Table 9).109 6-MeDCK (150) was much less
active, and 3-MeDCK (147) was inactive. Adding a methoxy group at position-3, -4, or -5
(151–153, respectively) resulted in retained activity relative to 146, while 6-OMeDCK (154)
was inactive (Table 9). Di-substitution or mono-substitution with larger alkyl or phenyl groups
was less favorable or unfavorable.109 In an effort to enhance water solubility and oral
bioavailability of DCK analogs, methyl groups substituted with various polar groups (-CH2X)
were added.110 While addition of aminomethyl or diethylaminomethyl groups at the C-3
position of 4-methylDCK decreased potency, both bromomethyl and hydroxymethyl groups
were favorable. Indeed, 3-bromomethyl-4-methylDCK (155) showed impressive EC50 and TI
values of 0.00011 μM / 186,000 (Figure 30).110 However, 3-hydroxymethyl-4-methylDCK
(156, HMDCK) (EC50 0.0042 μM, TI 6,000) was selected as a clinical trial candidate and
licensed by Panacos Pharmaceuticals, based on better oral bioavailability in rats. In mechanistic
studies, 146 and 156 were found to inhibit DNA-dependent DNA polymerase activity of the
viral reverse transcriptase (RT). However, unlike traditional RT inhibitors that block generation
of single stranded DNA from the RNA template, 146 and its analogs inhibit the production of
double-stranded vial DNA from the single-stranded DNA intermediates. The exact binding
site of these compounds has not yet been determined, but is possibly in the p51 subunit of HIV
RT, where 146 binding could interfere with second strand transfer.111 Regardless, the unique
mechanism of action makes 146 or future analogs potentially clinically useful.
In SAR studies, replacing an oxygen atom in the lactone ring of 146 with sulfur or nitrogen
led to analogs with significant potency, with EC50 values in the lower micromolar to nanomolar
range.112-114 For example, replacing the carbonyl oxygen of 4-methyl-DCK with sulfur (-
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OC=S) giving 158 (4-MeDCK thiolactone) led to no loss or improvement in potency when
assayed in CEM-SS cells (Figure 31).112 Similarly, replacing the alcoholic oxygen of the
lactone with nitrogen (-NHC=O, 159)113 or sulfur (-SC=O, 160)114 led to equipotent or slightly
more potent compounds, compared with 146 (-OC=O).
Dicamphanoylpyranochromone (DCP) Analogs
Another significant structural variation was to synthesize 3’R,4’R-di-O-(-)-camphanoyl-2’,2’-
dimethyldihydropyrano[2,3-f]chromone (DCP) analogs, which are positional isomers of DCK.
115 Among a series of mono- and di-substituted DCP derivatives, several compounds (161–
166) exhibited extremely high anti-HIV activity in the non-drug resistant strain assay, with
EC50 values ranging from 0.00032 to 0.0057 μM and remarkable therapeutic indexes (TI)
ranging from 5.6×103 to 1.16×105 (Table 10), which were similar to those of 148 (EC50 0.0059
μM, TI 6.6×103) and better than those of 146 (EC50 0.049 μM, TI 328). Even more promisingly,
some DCP analogs also showed activity against a multi-RT inhibitor resistant strain, HIV-1
RTMDR1, whereas most DCK analogs did not. An ethyl group was the optimal C-2 substituent
for activity against non-drug resistant and multi-drug resistant HIV strains. Thus, the most
significant compound was 2-Et-DCP (162), which showed the best anti-HIV activity in both
assays, including an EC50 value of 0.06 μM and TI of 718 against the multi-RT inhibitor
resistant HIV-1 strain (resistant to AZT, ddI, nevirapine, and other NNRTIs). In addition, 2-
substituted DCPs were less toxic to cells than the unsubstituted or 3-substituted compounds.
Due to their activity against drug-resistant HIV strains, DCP analogs may well be more
promising than DCK analogs for further development as clinical trial candidates. Figure 32
summarizes the status of the preclinical development of DCK and DCP derivatives.
Summary
Plant products still serve as an excellent source for modern drug discovery and development.
Through a medicinal chemistry approach, natural products with low bioactivity or known
compounds can be modified synthetically to improve their pharmacological profiles. Synthesis
of new compounds must be accompanied by appropriate biological assay screening to
successfully optimize a lead compound into a clinical trial candidate. As shown by the work
described above, academic laboratories can indeed successfully accomplish the goals of
bringing compounds into clinical trials.
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Flowchart for drug discovery and development of natural products-derived chemotherapeutic
agents. Qian, K.; Nitz, T. J.; Yu, D.; Allaway, G. P.; Morris-Natschke, S. L.; Lee, K. H. In
Natural Product Chemistry for Drug Discovery; Buss, A. D., Butler, M. S., Eds., RSC
Publishing: Cambridge, UK, 2010; p 376. Reproduced by permission of The Royal Society of
Chemistry.
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Complementarity of chemistry and biology: medicinal chemistry is an art of combining
chemistry and biology for drug discovery
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Structures of cytotoxic natural sesquiterpene lactones from Elephantopus mollis
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Structures of cytotoxic natural pseudoguaianolides from Helenium microcephalum
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Rank order of cytotoxic potency of helenalin analogs with varying degrees of molecular
unsaturation
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Structures of cytotoxic natural quassinoids from Brucea species
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Structures of cytotoxic synthetic quassinoids
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Structures of antileukemic natural flavonoids and lignan from Wikstroemia indica
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Structures of cytotoxic synthetic fluorinated 2-phenyl-4-quinolones
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Structures of cytotoxic psychorubrin and other quinone analogs
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Structures of cytotoxic dithiophenedione analogs
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Structures and antimitotic activity of colchicine, thiocolchicine, and thiocolchicone analogs
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Structures of podophyllotoxin, etoposide, and teniposide
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Structures of novel 4β-arylamino etoposide analogs
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Structures of cytotoxic curcuminoids
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Structures of cytotoxic tanshinones and neo-tanshinlactones
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Structures of cytotoxic natural Tylophora alkaloids and synthetic PBT analogs
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Mechanistic comparison of Tylophora alkaloids
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Structures of conjugated paclitaxel analogs
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Summary of the highlights of antitumor agents discovered by NPRL in clinical trials and
preclinical studies
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Structures of artemisinin and inactive, less active, and equipotent analogs
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Structure of antibacterial/antifungal agent licensed by Rohm & Haas
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Structures of betulinic acid, its natural precursor betulin, and its synthetic analog DSB
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Summary of clinical development of 133, an anti-AIDS compound discovered by NPRL
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Pharmacophores for anti-HIV maturation versus entry inhibitory 130-analogs
Lee Page 40














130-Derived HIV-1 entry inhibitors
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Comparison of C-3 mono-, C-28 mono-, and C-3,28 di-substituted triterpene HIV-1 inhibitors
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Structures of anti-HIV natural coumarin suksdorfin and synthetic analog DCK
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Potent disubstituted analogs of 146
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Biostereo-isomeric analogs of 146
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Summary of preclinical development of DCK and DCP derivatives, anti-HIV compounds
discovered by NPRL
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Synthesis of desmosdumotins B and C and analogs Reagents: a) NaOMe, RI; b)
TMSCHHN2; c) ArCHO, KOH; d) I2, DMSO then BBr3
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Synthesis of protoapigenone and analogs Reagents: a) MOMCl, K2CO3; b) KOH, 4-OBn-
PhCHO; c) I2, DMSO or Py; d) 10% Pd/CC, H2; e) TAIB, CH3CN/H2O for R3=OH or MeOH
for R3=OMe; f) 15% HCl/i-PrOH
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Synthesis of DCK analogs
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Anti-HIV Activity of 130-analogs in H9 Cell
cmpd R IC50 (μM) EC50 (μM) TI
130 H 13.0 1,4 9.3
133 (DSB) 7 0.00035 20,000
135 16 4.0 4














cmpd R IC50 (μM) EC50 (μM) TI
136 15.9 2.7 6.7














cmpd R IC50 (μM) EC50 (μM) TI
137 12.8 0.044 292
138 11.7 0.01 1,170














cmpd R IC50 (μM) EC50 (μM) TI
139 4.5 0.003 2,000
140 48 19 2.5















Anti-HIV Activity of Monomethylsuccinyl Analogs of 130
cmpd IC50 (μM) EC50 (μM) TI
S-141 33 0.0087 6,274
R-141 >40 0.12 >961
S-141+R-141 >40 0.016 >5,323
133 >40 0.0013 >30,555
AZT 1,870 0.034 55,330















Effect of Mono-methylation or –methoxylation on Activity of DCK
cmpd IC50 (μM) EC50 (μM)a TI
DCK (146) >16.1 0.05 >328
3-Me (147) -- No suppression --
4-Me (148) >39 0.006 6,600
5-Me (149) >16 0.008 >2,000
6-Me (150) >16 0.21 >72
3-OMe (151) >15 0.03 >533
4-OMe (152) >15 0.05 >300
5-OMe (153) >15 0.044 >350
6-OMe (154) -- No suppression --
AZT -- 0.044 --
a
HIV replication in H9 lymphocytes












































































































































































































































J Nat Prod. Author manuscript; available in PMC 2011 March 26.
